Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of melanoma~  * Regionally recurrent or distant metastatic disease~* Must have an established continuously proliferating cell line expanded to about 200 million cells that is free of stromal cells and contamination~* No active CNS metastases~  * Prior treatment for brain metastases or spinal cord compression allowed~ * No clear evidence of disease progression in the CNS~ * No concurrent pharmacologic doses of corticosteroids~PATIENT CHARACTERISTICS:~* Karnofsky performance status (PS) 70-100% OR ECOG PS 0-1~* Platelet count \> 100,000/mm³~* Hematocrit \> 30%~* Creatinine \< 2.0 mg/dL~* Bilirubin \< 2.0 mg/dL~* Albumin \> 3.0 mg/dL~* No significant hepatic or renal dysfunction~* No other invasive cancer within the past 5 years~* No active infection or other active medical condition that could be eminently life threatening, including any of the following:~  * Active blood clotting~ * Bleeding diathesis~* No ongoing transfusion requirement~* No underlying cardiac disease associated with known myocardial dysfunction~* No unstable angina related to atherosclerotic cardiovascular disease~* No known autoimmune disease~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~* Prior surgery, radiotherapy, chemotherapy, biological therapy (including sargramostim \[GM-CSF\]), or vaccine therapy allowed~* No concurrent anticancer therapy (e.g., hormone therapy for prostate or breast cancer)~* No concurrent digoxin or other medications for the treatment of heart failure~* No concurrent immunosuppressive therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).